Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD) Ended

2023-505635-13-00 Systemic lupus erythematosus 5 2022-06-10
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately t… Ended

2023-504737-41-00 Moderately to Severely Active Crohn's Disease 5 2022-06-10
Daratumumab in ME/CFS Ended

2024-512500-19-00 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 4 2022-04-29
A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis Ended

2023-507069-25-00 Amyloid Light Chain Amyloidosis 4 2022-04-29
New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients Ended

2023-510054-16-00 Primary Sjogren's syndrome 4 2022-04-26
Phase 3 Study of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis Ended

2023-506359-68-00 Active Proliferative Lupus Nephritis 5 2022-04-08
Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis Ended

2023-504597-37-00 Focal segmental glomerulosclerosis 5 2022-03-25
A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background N… Ended

2023-505696-74-00 systemic lupus erythematosus 5 2022-02-10
Efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia Ended

2023-509441-13-00 Warm autoimmune hemolytic anemia 4 2022-01-31
OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated ma… Ended

2024-512634-15-00 Patients with untreated mantle cell lymphoma 9 2022-01-05
Cladribine therapy in Myasthenia Ended

2024-517083-32-00 Myasthenia gravis 4 2021-12-17
A Study to Evaluate the Efficacy and Safety of BIIB059 (Litifilimab) in Adult Participants With Active Systemic Lupus Erythematosus Receivin… Ended

2023-505695-30-00 systemic lupus erythematosus 5 2021-11-30
Efficacy and Safety of Afimetoran Compared with Placebo in Participants with Active Systemic Lupus Erythematosus Ended

2023-504320-25-00 Active Systemic Lupus Erythematosus 4 2021-11-25
Long-term safety and tolerability of iptacopan in patients with Paroxysmal Nocturnal Hemoglobinuria Ended

2023-509843-28-00 Paroxysmal Nocturnal Hemoglobinuria (PNH) 5 2021-11-10
Efficacy of Abatacept vs Adalimumab in Early, Autoantibody positive Rheumatoid Arthritis (RA) and who did not respond well to methotrexate. Ended

2023-506450-20-00 Rheumatoid Arthritis 5 2021-11-05
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with Systemic Lupus Erythematosus (ALLEGORY) Ended

2023-504774-38-00 Systemic Lupus Erythematosus (SLE) 5 2021-11-04
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic… Ended

2023-506257-37-00 Active Psoriatic Arthritis 5 2021-10-29
Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus Ended

2024-513031-24-00 Moderate-to-severe Systemic Lupus Erythematosus (SLE) 10 2021-10-22
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic… Ended

2023-506256-25-00 Active Psoriatic Arthritis 5 2021-10-20
Guselkumab versus Placebo for the Treatment of Active Psoriatic Arthritis in Participants with Inadequate Response and/or Intolerance to One… Ended

2023-504715-33-00 Psoriatic Arthritis 5 2021-09-27
A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with prim… Ended

2023-508690-92-00 IgA Nephropathy 11 2021-09-20
A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended

2023-506368-14-00 Systemic lupus erythematosus (SLE) 5 2021-09-07
A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended

2023-504734-21-00 Psoriatic arthritis (PsA) 5 2021-08-30
Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Ended

2023-504716-15-00 Psoriatic Arthritis 6 2021-08-06